Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) Operating Margin (2018 - 2025)

Cue Biopharma's Operating Margin history spans 8 years, with the latest figure at 353.42% for Q3 2025.

  • For Q3 2025, Operating Margin fell 8915.0% year-over-year to 353.42%; the TTM value through Sep 2025 reached 537.58%, down 5811.0%, while the annual FY2024 figure was 446.86%, 50303.0% up from the prior year.
  • Operating Margin for Q3 2025 was 353.42% at Cue Biopharma, down from 292.45% in the prior quarter.
  • Across five years, Operating Margin topped out at 95.62% in Q4 2021 and bottomed at 50346.15% in Q2 2022.
  • The 5-year median for Operating Margin is 737.8% (2024), against an average of 4982.41%.
  • The largest annual shift saw Operating Margin tumbled -4996999bps in 2022 before it surged 4936879bps in 2023.
  • A 5-year view of Operating Margin shows it stood at 95.62% in 2021, then plummeted by -10196bps to 9845.03% in 2022, then surged by 92bps to 760.0% in 2023, then rose by 20bps to 611.23% in 2024, then soared by 42bps to 353.42% in 2025.
  • Per Business Quant, the three most recent readings for CUE's Operating Margin are 353.42% (Q3 2025), 292.45% (Q2 2025), and 2921.38% (Q1 2025).